What is the difference between amyloidosis and sarcoidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Key Differences Between Amyloidosis and Sarcoidosis

Amyloidosis and sarcoidosis are distinct systemic disorders with different pathophysiology, diagnostic features, and treatment approaches, with amyloidosis carrying a generally worse prognosis due to progressive organ dysfunction from protein deposition.

Pathophysiology

Amyloidosis

  • Characterized by extracellular deposition of misfolded proteins (amyloid fibrils) in various organs 1
  • Multiple types based on precursor protein:
    • AL (light chain) amyloidosis: Most common type, caused by plasma cell dyscrasia with unstable immunoglobulin light chains 2
    • ATTR (transthyretin) amyloidosis: Either hereditary (mutant) or wild-type (senile) 2
    • AA (reactive) amyloidosis: Caused by serum amyloid A protein deposition during chronic inflammation 2
    • Dialysis-related: Involves β-microglobulin 2 1

Sarcoidosis

  • Characterized by non-caseating granulomatous inflammation 3
  • Immune-mediated disorder with formation of epithelioid and giant cell granulomas 3
  • Can affect multiple organs but primarily involves lungs, lymph nodes, and skin

Organ Involvement

Amyloidosis

  • Typically affects multiple organs (median of 2 sites) 1
  • Most commonly affects heart and kidneys 1
  • Cardiac involvement is the main driver of prognosis and mortality 2
  • Other affected organs include liver, GI tract, and nervous system 2

Sarcoidosis

  • Primarily affects lungs and lymph nodes 3
  • Can also involve liver, spleen, skin, eyes, and heart 3
  • Rarely causes AA amyloidosis as a complication 3, 4

Clinical Presentation

Amyloidosis

  • Heart failure with preserved ejection fraction 1
  • Proteinuria (often nephrotic range) 1
  • Peripheral and autonomic neuropathy 1
  • Carpal tunnel syndrome (often precedes other symptoms) 1
  • Macroglossia, periorbital purpura 1
  • GI symptoms: early satiety, weight loss, alternating constipation/diarrhea 1

Sarcoidosis

  • Respiratory symptoms: cough, dyspnea, chest pain
  • Lymphadenopathy (often mediastinal)
  • Skin lesions (erythema nodosum)
  • Constitutional symptoms: fatigue, fever, weight loss
  • Ocular manifestations: uveitis, conjunctivitis

Diagnostic Features

Amyloidosis

  • Gold standard: Tissue biopsy with Congo red staining showing apple-green birefringence under polarized microscopy 2
  • Biopsy sites: affected organs, abdominal fat pad, rectum, or bone marrow 1
  • Cardiac imaging: echocardiography showing ventricular wall thickening with low QRS voltage on ECG 2
  • Laboratory: Serum/urine monoclonal proteins, elevated BNP/NT-proBNP 2
  • Nuclear imaging: Technetium Tc 99m dicarboxypropane diphosphonate to distinguish AL from ATTR 2

Sarcoidosis

  • Tissue biopsy showing non-caseating granulomas 3
  • Chest radiography/CT showing bilateral hilar lymphadenopathy and pulmonary infiltrates
  • Elevated serum angiotensin-converting enzyme (ACE) levels
  • Gallium-67 scintigraphy or FDG-PET showing characteristic uptake patterns 5

Treatment Approaches

Amyloidosis

  • AL amyloidosis: Target the underlying plasma cell clone
    • ASCT for eligible patients (~20%) 2
    • Bortezomib-based regimens for ASCT-ineligible patients 2
    • Daratumumab emerging as standard of care 2
  • ATTR amyloidosis: Tafamidis for cardiac involvement to reduce mortality and hospitalization 6
  • Supportive care for organ dysfunction 2
    • Cautious use of diuretics
    • Avoid β-blockers, calcium channel blockers, and digoxin in cardiac amyloidosis 2

Sarcoidosis

  • Often self-limiting and may not require treatment
  • Corticosteroids as first-line therapy for symptomatic disease 3, 4
  • Steroid-sparing agents: methotrexate, azathioprine, hydroxychloroquine
  • If AA amyloidosis complicates sarcoidosis, combination of corticosteroids and colchicine 3

Prognosis

Amyloidosis

  • Varies by type and organ involvement:
    • AL with cardiac involvement: median survival 13 months (4 months if heart failure) 1
    • Hereditary ATTR: median survival 70 months 1
    • Wild-type ATTR: median survival 75 months 1
    • AA amyloidosis: median survival 25 months 1

Sarcoidosis

  • Generally favorable outcome in most cases
  • Chronic in 10-30% of patients
  • Mortality rate 1-5%, usually due to pulmonary fibrosis or cardiac involvement

Relationship Between the Two Conditions

  • AA amyloidosis can rarely complicate chronic sarcoidosis 3, 4
  • When this occurs, both conditions should be treated simultaneously, typically with corticosteroids and colchicine 3

Key Clinical Pearls

  • Consider amyloidosis in patients with unexplained heart failure with preserved ejection fraction, unexplained proteinuria, and peripheral neuropathy 1
  • Early diagnosis of amyloidosis is crucial before irreversible organ damage occurs 2
  • Sarcoidosis diagnosis requires exclusion of other causes of granulomatous inflammation
  • Both conditions require multidisciplinary management due to multi-organ involvement

References

Guideline

Amyloidosis Diagnosis and Presentation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[AA amyloidosis complicating sarcoidosis].

La Revue de medecine interne, 1999

Research

Radionuclide Imaging of Cardiac Amyloidosis and Sarcoidosis: Roles and Characteristics of Various Tracers.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.